2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 166

Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Abstract Number: 206

Risk Factors for Increased Extrusion of the Meniscus Body in Subjects Free of Radiographic Knee Osteoarthritis: 6-Year MRI Data from the Osteoarthritis Initiative
Abstract Number: 2990

Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study
Abstract Number: 236

Risk Factors for Prevalent and Progressive Bone Deficits Among Adult Men and Women with Cystic Fibrosis
Abstract Number: 809

Risk Factors for Severe Ischemic Complications in Takayasu Arteritis: A French Multicenter Retrospective Cohort of 182 Patients
Abstract Number: 2266

Risk Factors for Treatment Failure in Osteoporotic Patients with Rheumatoid Arthritis
Abstract Number: 230

Risk Factors That Predict Poor Bone Health in Those Aged over 75 Years – a Cross Sectional Study
Abstract Number: 2154

Risk for Developing Adult T-Cell Leukemia in Patients with Human T Lymphotropic Virus Type-I Carrier Receiving Immunosuppressive Therapy
Abstract Number: 823

Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol
Abstract Number: 1848

Risk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour-Necrosis Factor Alpha Inhibition
Abstract Number: 2628

Risk of Cancer Is Not Increased in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study
Abstract Number: 2642

Risk of Cardiovascular Events in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study
Abstract Number: 2545

Risk of Cervical Root and Incisal Caries in Patients with Sjogren’s Syndrome
Abstract Number: 970

Risk of Developing Antiphospholipid Syndrome Following Infection: A Systematic Review and Meta-Analysis of Observational Studies
Abstract Number: 483

Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].